Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 10, 2015, Pages 1200-1210

  Jairath, V ^a,b   Khanna, R ^c,d   Zou, G Y ^c,d   Stitt, L ^c   Mosli, M ^c,d,e   Vandervoort, M K ^c   D'Haens, G ^c,f   Sandborn, W J ^c,g   Feagan, B G ^c,d   Levesque, B G ^c,g  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; PLACEBO; VEDOLIZUMAB;

AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; DEFECATION HABIT; DISEASE ACTIVITY; EFFECT SIZE; ENDOSCOPY; HUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT REPORTED OUTCOME; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RECTUM HEMORRHAGE; REMISSION; SELF REPORT; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; VALIDATION STUDY; ADULT; COLITIS, ULCERATIVE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL HEMORRHAGE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

ADULT; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; ENDOSCOPY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT OUTCOME ASSESSMENT; UNITED STATES;

EID: 84943618535     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13408     Document Type: Article

References (19)

1. D'Haens G, Sandborn WJ, Feagan BG, et al,. A review of activity indices and efficacy endponts for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-86.
2. Schroeder KW, Tremaine WJ, Ilstrup DM,. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9.
3. Sutherland LR, Martin F,. 5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada. Dig Dis Sci 1987; 32 (12 Suppl.): 64S-6S.
4. Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
5. Zagadailov E, Fine M, Shields A,. Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers. Am Health Drug Benefit 2013; 6: 264-74.
6. Marquis P CM, Emery M,. The role of health-related quality of life data in the drug approval processes in the US and Europe: a review of guidance documents and authorizations of medicinal products from 2006 to 2010. Pharm Med [serial on the Internet] 2011; 25: 147-60.
7. Patrick DL, Burke LB, Gwaltney CJ, et al,. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2-assessing respondent understanding. Value Health 2011; 14: 978-88.
8. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. US Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER); Center for Devices and Radiological Health (CDRH) [serial on the Internet]. 2009.
9. A study to evaluate the safety and efficacy of Ustekinumab induction and maintenance therapy in participants with moderately to severely active ulcerative colitis (UNIFI). Available at: https://clinicaltrialsgov/ct2/show/NCT02407236 (accessed July 2015).
10. Feagan BG, Sandborn WJ, D'Haens G, et al,. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013; 145: 149-57 e2.
11. Kamm MA, Sandborn WJ, Gassull M, et al,. Once-daily high concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75.
12. Feagan BG, Greenberg GR, Wild G, et al,. Treatment of ulcerative colitis with a humanized antibody to the a4b7 integrin. N Engl J Med 2005; 352: 2499-507.
13. Lahiff C, Safaie P, Awais A, et al,. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2013; 37: 786-94.
14. Su CY, Lewis JD, Goldberg B, et al,. Factors that influence placebo remission rates in clinical trials of active ulcerative colitis: a meta-analysis. Gastroenterology 2005; 128 (Suppl. 2): A-326.
15. Enck P, Bingel U, Schedlowski M, et al,. The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discovery 2013; 12: 191-204.
16. Bodger K, Ormerod C, Shackcloth D, et al,. Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaire. Gut 2014; 63: 1092-102.
17. Higgins PD, Schwartz M, Mapili J, et al,. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol 2005; 100: 355-61.
18. Sands BE, Sandborn WJ, Creed TJ, et al,. Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. Gastroenterology 2012; 143: 356-64 e1.
19. Dhanda AD, Creed TJ, Greenwood R, et al,. Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials? Inflamm Bowel Dis 2012; 18: 2056-62.